News
No revenue reported as Terns remains a clinical-stage, pre-commercial biotech. A strong cash position of $315.4 million as of Q2 2025 is expected to fund operations into 2028.
Sales up 18pc, profits up 32pc — yet Ozempic maker Novo Nordisk feels the weight of US competition
Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit today, but rising competition is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results